12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

EGEN-001: Phase I started

Egen said the Gynecologic Oncology Group (GOG) began an open-label, dose-escalation, U.S. Phase I trial to evaluate 18-36 mg/m 2 intraperitoneal EGEN-001 weekly plus...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >